Metabolic interaction between fluoxetine and clomipramine: A case report

Pharmacopsychiatry

Volumn 29, Issue 1, 1996, Pages 38-41

  Balant Gorgia, A E ^a,b,c,d   Ries, C ^b,c   Balant, L P ^b  

^a Therapeutic Drug Monitoring Unit   (Switzerland)

^b Department of Psychiatry ^*  (Switzerland)

^c University Hospital   (Switzerland)

^d U Monitoring Therapeutique Belle I   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORCLOMIPRAMINE; NORTRIPTYLINE;

AGED; ARTICLE; CARDIOTOXICITY; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; FEMALE; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0030051127     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979541     Document Type: Article

References (21)

1. Aranow, R. B., J. I. Hudson, H. G. Pope, T. A. Grady, T. A. Laage, I. R. Bell, J. O. Cole: Elevated antidepressant plasma levels after addition of fluoxetine. Amer. J. Psychiatry 146 (1989) 911-913
2. Balant-Gorgia. A. E., L. P. Balant, C. Genet, P. Dayer, J. M. Aeschlimann, G. Garrone: Importance of oxidative polymorphism and levomepromazine treatment on the steady-state concentrations of clomipramine and its major metabolites. Eur. J. Clin. Pharmacol. 31 (1986) 449-455
3. Balant-Gorgia, A. E., L. P. Balant, G. Garrone: High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther. Drug Monitor. 11 (1989) 415-420
4. Baumann, P., G. Bertschy: Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. Nord. J. Psychiatry 47 (Suppl. 30) (1993) 13-19
5. Bell, I. R., J. O. Cole: Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J. Clin. Psychopharmacol. 8 (1988) 447-448
6. Benfield, P., R. C. Heel, S. P. Lewis: Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32 (1986) 481-508
7. Bocksberger, J. P., M. Gex-Fabry, L. Gauthey, A. E. Balant-Gorgia: Clomipramine therapy in the geriatric hospital: Experience with therapeutic drug monitoring. Ther. Drug Monitor. 16 (1994) 113-119
8. Brøsen, K., E. Skjelbo: Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of sparteine/debrisoquin oxidation polymorphism. Br. J. Clin. Pharmacol. 32 (1991) 136-137
9. Downs, J. M., A. D. Downs, T. L. Rosenthal, N. Deal, H. S. Akiskal: Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. J. Clin. Psychiatry 50 (1989) 226-227
10. Goodnick, P. J.: Influence of fluoxetine on plasma levels of desipramine. Am. J. Psychiatry 146 (1989) 552
11. Goodnick, P. J.: Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol. Bull. 27 (1991) 503-512
12. Nelson, J. C., C. M. Mazure, M. B. Bowers, P. I. Jatlow: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48 (1991) 303-307
13. Otton, S. V., D. Wu, R. T. Joffe, S. W. Cheung, E. M. Sellers: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53 (1993) 401-409
14. Preskorn, S. H., J. H. Beber, J. C. Faul, R. M. A. Hirschfeld: Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am. J. Psychiatry 147 (1990) 532
15. Preskorn, S. H., J. Alderman, M. Chung, W. Harrison, M. Messig, S. Harris: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacology 14 (1994) 90-98
16. Suckow, R. F., S. P. Roose, T. B. Cooper: Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine. Biol. Psychiatry 31 (1992) 200-204
17. Vandel, S., G. Bertschy, G. Bonin, S. Neselof, T. H. François, B. Vandel, D. Sechter, P. Bizouard: Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25 (1992) 202-207
18. Vaughan, D. A.: Interaction of fluoxetine with tricyclic antidepressants. Am. J. Psychiatry 145 (1988) 1478
19. von Ammon Cavanaugh, S.: Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 31 (1990) 273-276
20. Weilburg, J. B., J. F. Rosenbaum, J. Biederman, G. S. Sachs, M. H. Pollack, K. Kelly: Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J. Clin. Psychiatry 50 (1989) 447-449
21. Westermeyer, J.: Fluoxetine-induced tricyclic toxicity: extent and duration. J. Clin. Pharmacol. 31 (1991) 388-392